Spots Global Cancer Trial Database for JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
Official Title: A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients With Advanced Solid Tumors
Study ID: NCT04720976
Study Description
Brief Summary: To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.
Detailed Description: To assess the safety and tolerability and determine the Recommended phase 2 dose (RP2D) of JAB-3312 in combination with PD1 inhibitor or MEK inhibitor in patients with advanced solid tumors.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Phoenix, Arizona, United States
Research Site, Scottsdale, Arizona, United States
Research Site, Los Angeles, California, United States
Research Site, New Haven, Connecticut, United States
Research Site, Jacksonville, Florida, United States
Research Site, Orange City, Florida, United States
Research Site, Chicago, Illinois, United States
Research Site, Indianapolis, Indiana, United States
Research Site, Detroit, Michigan, United States
Research Site, Rochester, Minnesota, United States
Research Site, Saint Louis, Missouri, United States
Research Site, New York, New York, United States
Research Site, Oklahoma City, Oklahoma, United States
Research Site, Houston, Texas, United States
Research Site, Salt Lake City, Utah, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
